Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals (Nasdaq: TNXP) is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases and rare diseases. Its marketed products include TONMYA, a sublingual cyclobenzaprine treatment for adult fibromyalgia launched in… From the company’s description.
Over the twelve months to Jun 30, 2026, Tonix Pharmaceuticals Holding Corp. reported revenue of $29.10M, up 196.0% from a year earlier, and a net loss of $159.67M. Its operating margin was −568.4%, and operations used $152.99M in cash. In fiscal 2025, it reported revenue of $13.11M, up 29.8% from fiscal 2024, and a net loss of $124.02M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tonix Pharmaceuticals Holding Corp. does
In the company’s own words
Tonix Pharmaceuticals (Nasdaq: TNXP) is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases and rare diseases. Its marketed products include TONMYA, a sublingual cyclobenzaprine treatment for adult fibromyalgia launched in November 2025, and Zembrace SymTouch and Tosymra, prescription products for acute migraine in adults. The company sells through an integrated commercial platform with sales, market access, distribution and patient-support capabilities, serving prescribers and patients through healthcare practices and pharmacy channels. Its development pipeline includes candidates for major depressive disorder, acute stress disorder, Lyme disease prevention, transplant rejection, cocaine intoxication, Prader-Willi syndrome, mpox and smallpox, viral infections, neuropathic pain, and gastric and colorectal cancers. Tonix acquired Zembrace SymTouch and Tosymra in 2023; TONMYA is its first internally developed FDA-approved product. The company operates research facilities in Maryland and Massachusetts. In 2025, it had approximately 90 U.S. sales representatives promoting TONMYA. Its website is www.tonixpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BERKELEY HEIGHTS, NJ
- Fiscal year end
- December
- CIK
- 1430306
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tonix Pharmaceuticals Holding Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tonix Pharmaceuticals Holding Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tonix Pharmaceuticals Holding Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tonix Pharmaceuticals Holding Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tonix Pharmaceuticals Holding Corp.'s last four quarterly filings that the numbers alone won't show?”